Lucid Diagnostics reports preliminary Q4 adjusted EPS (23c), consensus (26c)

Reports preliminary Q4 revenue $1.04M, consensus $1.05M. “We are very pleased with the excellent progress Lucid has made on multiple fronts in the fourth quarter and recent weeks,” said Lishan Aklog, M.D., Lucid’s Chairman and CEO. “We saw solid revenue growth on stable test volume and our revenue cycle management processes are yielding improving allowances and stable pricing. Our #CYFT program targeting firefighters and other groups is thriving and we have a robust pipeline of scheduled high-volume testing events. Most importantly, we have rapidly built our clinical validity and clinical utility evidence base to drive positive medical policy coverage, including what now we believe is line of sight to Medicare coverage. Equipped with sufficient data, we have for the first time engaged with medical directors at major commercial payors to request positive coverage. Our direct contracting initiative is also accelerating and we are excited about the near-term prospects of delivering contracts, testing and revenue.”